Anika Narrows Losses Amid Strategic Divestitures, Revenue Dip

TL;DR

**ANIK is shedding dead weight and showing signs of a turnaround, but revenue is still a concern; watch for sustained profitability post-divestiture.**

AI Summary

Anika Therapeutics, Inc. (ANIK) reported a net loss of $2.3 million for the three months ended September 30, 2025, a significant improvement from the $29.9 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $11.2 million, compared to $34.5 million in 2024. Revenue decreased to $27.8 million for the three months ended September 30, 2025, down from $29.6 million in 2024, and to $82.2 million for the nine months, down from $89.3 million. The company's strategic shift to focus on OA Pain Management and Regenerative Solutions businesses led to the sale of Arthrosurface in October 2024 and Parcus Medical in March 2025. These divestitures contributed to a gain from discontinued operations of $0.8 million in Q3 2025, a stark contrast to the $28.1 million loss in Q3 2024. Operating expenses decreased to $18.8 million for the quarter, from $19.5 million in 2024, primarily due to reduced selling, general & administrative expenses. Cash and cash equivalents increased to $58.0 million as of September 30, 2025, from $55.6 million at December 31, 2024, driven by $6.6 million in net cash provided from operating activities.

Why It Matters

Anika's strategic pivot, marked by the divestiture of Arthrosurface and Parcus Medical, is a critical move for investors seeking a clearer focus on its core OA Pain Management and Regenerative Solutions. While revenue declined, the substantial reduction in net loss from $29.9 million to $2.3 million quarter-over-quarter suggests improved operational efficiency post-divestiture. This focus could enhance competitive positioning against larger orthopedic players by concentrating resources on high-growth, less invasive solutions. Employees in the remaining core businesses might see increased stability and investment, while customers could benefit from a more specialized product pipeline. The broader market will watch if this streamlined approach can translate into sustainable profitability and market share gains in a competitive medical device landscape.

Risk Assessment

Risk Level: medium — The company reported a net loss of $2.3 million for the quarter and $11.2 million for the nine months ended September 30, 2025, indicating ongoing unprofitability from continuing operations. Revenue also decreased to $27.8 million for the quarter and $82.2 million for the nine months, suggesting challenges in its core business despite the strategic shift.

Analyst Insight

Investors should closely monitor Anika's revenue growth in its core OA Pain Management and Regenerative Solutions segments in upcoming quarters. While the reduction in net loss is positive, sustained profitability and top-line expansion are crucial to validate the strategic divestitures. Consider holding if you believe in the long-term potential of their focused strategy, but be prepared for continued volatility.

Financial Highlights

debt To Equity

0.16

revenue

$82.2M

operating Margin

-14.2%

total Assets

$189.4M

total Debt

$30.0M

net Income

-$11.2M

eps

N/A

gross Margin

54.3%

cash Position

$58.0M

revenue Growth

-8.0%

Revenue Breakdown

Key Numbers

• $2.3M — Net Loss (Q3 2025) (Significant improvement from $29.9M net loss in Q3 2024)
• $11.2M — Net Loss (YTD Q3 2025) (Reduced from $34.5M net loss in YTD Q3 2024)
• $27.8M — Revenue (Q3 2025) (Decrease from $29.6M in Q3 2024)
• $82.2M — Revenue (YTD Q3 2025) (Decrease from $89.3M in YTD Q3 2024)
• $0.8M — Income from Discontinued Operations (Q3 2025) (Shift from $28.1M loss in Q3 2024 due to divestitures)
• $58.0M — Cash and Cash Equivalents (Sept 30, 2025) (Increase from $55.6M at Dec 31, 2024)
• $6.6M — Net Cash from Operating Activities (YTD Q3 2025) (Increased from $3.8M in YTD Q3 2024)
• $7.0M — Promissory Note from Arthrosurface Sale (Non-interest-bearing note received as consideration)
• $4.5M — Cash from Parcus Medical Sale (Cash consideration received at closing)

Key Players & Entities

• Anika Therapeutics, Inc. (company) — Registrant
• Arthrosurface (company) — Former wholly-owned subsidiary, sold October 31, 2024
• Parcus Medical, LLC (company) — Former subsidiary, sold March 7, 2025
• Phoenix Brio, Incorporated (company) — Buyer of Arthrosurface
• Medacta Americas Manufacturing, Inc. (company) — Buyer of Parcus Medical
• U.S. Food and Drug Administration (regulator) — Regulatory body for life sciences industry
• Securities and Exchange Commission (regulator) — Regulatory body for financial filings
• Financial Accounting Standards Board (regulator) — Accounting standards setter

FAQ

Risk Factors

• Dependence on Divested Businesses [medium — financial]: The company's strategic shift involved selling Arthrosurface and Parcus Medical. While this improved profitability, it significantly reduced overall revenue from $89.3M (YTD 2024) to $82.2M (YTD 2025). Future revenue growth will depend on the performance of the remaining OA Pain Management and Regenerative Solutions segments.
• Integration of Divestitures and Focus Shift [medium — operational]: The sale of Arthrosurface in October 2024 and Parcus Medical in March 2025 represents a significant operational shift. Successfully integrating these changes and focusing resources on the remaining segments is critical for future success and requires careful management of resources and strategy.
• Reduced Gross Profit Margins [medium — financial]: Gross profit decreased from $58.9M in the first nine months of 2024 to $44.6M in the same period of 2025. This decline, coupled with a decrease in revenue, suggests potential pressure on pricing or increased cost of goods sold for the remaining product lines.
• Continued Operating Losses [medium — financial]: Despite improvements, the company reported a loss from operations of $11.7M for the nine months ended September 30, 2025, compared to a loss of $4.4M in the prior year. This indicates ongoing challenges in generating operating profit from the core business.
• Product Development and Approval Risks [high — regulatory]: As a medical device company, Anika Therapeutics is subject to stringent regulatory approval processes for new products. Delays or failures in obtaining regulatory clearance (e.g., FDA) for innovations in OA Pain Management and Regenerative Solutions could hinder revenue growth and market penetration.
• Competition in Medical Devices [medium — market]: The markets for OA Pain Management and Regenerative Solutions are competitive, with established players and emerging technologies. Anika's ability to differentiate its offerings and gain market share will be crucial, especially given the recent divestitures.

Industry Context

Anika Therapeutics operates in the competitive medical device sector, specifically focusing on OA Pain Management and Regenerative Solutions. This industry is characterized by rapid technological advancements, significant R&D investment, and stringent regulatory oversight from bodies like the FDA. Companies often pursue strategic divestitures to streamline operations and focus on high-growth areas, as Anika has done.

Regulatory Implications

As a medical device company, Anika is subject to rigorous FDA regulations for product development, manufacturing, and marketing. The company must ensure ongoing compliance with quality system regulations and post-market surveillance requirements. Any failure to comply could result in product recalls, fines, or suspension of operations.

What Investors Should Do

1. Monitor revenue trends in OA Pain Management and Regenerative Solutions.
2. Analyze the sustainability of improved net loss figures.
3. Evaluate the impact of reduced operating expenses.
4. Assess the cash burn rate and runway.

Key Dates

• 2024-10-01: Sale of Arthrosurface — Part of a strategic shift to focus on core businesses, contributing to a gain from discontinued operations in subsequent periods.
• 2025-03-01: Sale of Parcus Medical — Further divestiture aligned with the company's strategy, impacting revenue and operational structure.
• 2025-09-30: End of Q3 2025 — Reporting period for the 10-Q, showing improved net loss and increased cash position.
• 2025-09-30: Cash and cash equivalents balance — $58.0M, an increase from $55.6M at year-end 2024, indicating improved liquidity.
• 2025-09-30: Net loss for Q3 2025 — $2.3M, a significant improvement from $29.9M in Q3 2024, reflecting successful cost management and divestiture gains.

Glossary

Discontinued Operations

Represents the results of business segments that have been or will be disposed of. Gains or losses from these operations are reported separately. (Anika Therapeutics reported a gain from discontinued operations of $0.8M in Q3 2025 due to the sale of Arthrosurface and Parcus Medical, significantly improving the net income picture.)

Right-of-use assets

Assets recognized under lease accounting standards, representing the right to use an underlying asset for the lease term. (These assets, valued at $24.2M as of Sept 30, 2025, reflect the company's long-term lease obligations, primarily for facilities.)

Accumulated other comprehensive loss

A component of equity that includes unrealized gains and losses that have not yet been realized as part of net income. (Anika's accumulated other comprehensive loss was $(4.9M) as of Sept 30, 2025, down from $(6.8M) at year-end 2024, indicating some improvement in these unrealized items.)

Goodwill

An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net assets. (Goodwill increased to $8.1M as of Sept 30, 2025, from $7.1M at year-end 2024, potentially indicating recent acquisitions or adjustments to prior acquisition valuations.)

Promissory Note

A written promise to pay a specific sum of money to a specific person or entity, either on demand or at a specified future date. (Anika received a $7.0M non-interest-bearing promissory note from the Arthrosurface sale, which is a form of deferred consideration.)

Year-Over-Year Comparison

Compared to the prior year, Anika Therapeutics has significantly improved its net loss, reducing it from $29.9M in Q3 2024 to $2.3M in Q3 2025, and from $34.5M year-to-date to $11.2M. This improvement is largely driven by gains from discontinued operations following the sale of Arthrosurface and Parcus Medical, which also led to a revenue decrease from $29.6M to $27.8M for the quarter and $89.3M to $82.2M year-to-date. Operating expenses have been reduced, particularly SG&A, contributing to the improved bottom line, and the cash position has strengthened to $58.0M.

Key Financial Figures

• $0.01 — ch Registered Common Stock, par value $0.01 per share ANIK NASDAQ Global Select

Filing Documents

• anik20250930_10q.htm (10-Q) — 1493KB
• ex_878299.htm (EX-31.1) — 13KB
• ex_878300.htm (EX-31.2) — 13KB
• ex_878301.htm (EX-32.1) — 6KB
• 0001171843-25-007032.txt ( ) — 7271KB
• anik-20250930.xsd (EX-101.SCH) — 60KB
• anik-20250930_def.xml (EX-101.DEF) — 420KB
• anik-20250930_lab.xml (EX-101.LAB) — 372KB
• anik-20250930_pre.xml (EX-101.PRE) — 465KB
• anik-20250930_cal.xml (EX-101.CAL) — 52KB
• anik20250930_10q_htm.xml (XML) — 1196KB

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 Part II Other Information 26 Item 1.

Legal Proceedings

Legal Proceedings 26 Item 1A.

Risk Factors

Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 27 Item 3. Defaults Upon Senior Securities 27 Item 4. Mine Safety Disclosures 27 Item 5. Other Information 27 Item 6. Exhibits 28

Signatures

Signatures 29 References in this Quarterly Report on Form 10-Q to "we," "us," "our," "our company," and other similar references refer to Anika Therapeutics, Inc. and its subsidiaries unless the context otherwise indicates. ANIKA, ANIKA THERAPEUTICS, CINGAL, HYAFF, HYALOFAST, INTEGRITY, MONOVISC, ORTHOVISC, and TACTOSET are our registered trademarks that appear in this Quarterly Report on Form 10-Q. For convenience, these trademarks appear in this Quarterly Report on Form 10-Q without and symbols, but that practice does not mean that we will not assert, to the fullest extent under applicable law, our rights to the trademarks. This Quarterly Report on Form 10-Q also contains trademarks and trade names that are the property of other companies and licensed to us. PART I: FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS Anika Therapeutics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except per share data) (unaudited) September 30, December 31, ASSETS 2025 2024 Current assets: Cash and cash equivalents $ 57,990 $ 55,629 Accounts receivable, net 22,187 23,594 Inventories 16,284 23,809 Prepaid expenses and other current assets 5,129 5,494 Current assets held for sale - 5,126 Total current assets 101,590 113,652 Property and equipment, net 40,684 38,994 Right-of-use assets 24,226 25,685 Other long-term assets 5,507 5,656 Notes receivable 6,478 5,935 Deferred tax assets 1,251 1,177 Intangible assets, net 1,650 2,490 Goodwill 8,051 7,125 Non-current assets held for sale - 2,026 Total assets $ 189,437 $ 202,740 LIABILITIES AND STOCKHOLDERS ' EQUITY Current liabilities: Accounts payable $ 4,732 $ 5,617 Accrued expenses and other current liabilities 14,357 13,567 Current liabilities held for sale - 4,122 Total current liabilities 19,089 23,306 Other long-term liabilities 761 772 Lease liabilities 22,782 24,014 Non-current liabilities held for sale - 659 Commitments and contingencies (Note 11) Stockholders' equity: Preferred stock, $ 0.01 par value; 1,250 shares authorized, no shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively - - Common stock, $ 0.01 par value; 90,000 shares authorized, 15,355 issued and 14,421 outstanding and 15,010 issued and 14,416 outstanding at September 30, 2025 and December 31, 2024, respectively 144 144 Additional paid-in-capital 91,105 88,961 Accumulated other comprehensive loss ( 4,939 ) ( 6,783 ) Retained earnings 60,495 71,667 Total stockholders' equity 146,805 153,989 Total liabilities and stockholders' equity $ 189,437 $ 202,740 The accompanying notes are an integral part of these unaudited cond

View Full Filing

View this 10-Q filing on SEC EDGAR